Background: Acquired thrombocytopenia is associated with an increased risk of adverse events of
coronary artery bypass grafting surgery (CABG), and percutaneous coronary intervention (PCI) [1] [2] [3] . However, these therapies may cause acquired thrombocytopenia and have been strongly associated with an increased risk of hemorrhagic and ischemic complications, as well as early mortality [4] [5] [6] [7] [8] . To date, few data exist regarding the impact of acquired thrombocytopenia on the long-term outcomes of patients who underwent elective PCI for stable angina or low-risk ACS. The aim of our study was to evaluate the incidence, long-term prognostic significance and independent predictors of acquired thrombocytopenia in a large, contemporary, unselected, real-world cohort of patients who underwent elective PCI. 
| M E TH ODS

| Study population
| Data collection
We collected data on baseline, initial medical contact, medical history, angiographic, laboratory tests, treatment, and clinical outcomes. Clinical data were collected by reviewing medical records. Laboratory analyses were performed in the Fuwai Hospital Biochemistry Laboratory. Echocardiograms and angiograms were interpreted by an independent core laboratory in Fuwai Hospital.
The incidence of death, myocardial infarction (MI), bleeding, or target vessel revascularization (TVR) post-hospital discharge were adjudicated using medical records or telephone questionnaire.
| Follow-up
Clinical follow-up was performed by trained cardiologists via outpatient visit, telephone, or letter. All patients were advised to return to the clinic if they experienced symptoms indicating acute MI, including chest pain, dyspnea, diaphoresis, and nausea. We kept at least two telephone numbers of each patient and his/her family member. Clinical follow-up was performed at 1 month, 6 months, 12 months, and annually postdischarge. Patients or their family members were asked if death, MI, repeat revascularization, or bleeding occurred post-discharge. When no contact was achieved after three phone call attempts, we sent a letter to the patient inquiring about the above items.
| Clinical end points
The primary study outcomes included death and major adverse cardiovascular events (MACE) at the 30-month follow-up. The value of MACE was defined as a composite of all-cause death, MI and any revascularization. Death were classified as cardiac or non-cardiac in origin. All end points were defined according to the Academic Research Consortium (ARC) definitions [9] . Secondary outcomes included major or minor bleeding according to the Bleeding Academic Research Consortium (BARC) scale [10] . We categorized major bleeding as type 2, 3, or 5 stent thrombosis (0.5%vs. 0.1%, P 5 0.0504) than those without thrombocytopenia; however, these differences were not significant. KaplanMeier event curves showed that compared with patients without thrombocytopenia, those who developed thrombocytopenia had a two-fold increased risk for all-cause death ( Figure 2 ) and cardiogenic death ( Figure 3 ) and a trend toward higher risk for MACE (Figure 4 ). 
| D I SCUSSION
The principal findings of this large-scale retrospective study of patients who underwent elective PCI are the following: (1) acquired thrombocytopenia was common and occurred in approximately one in 13 patients; (2) the 30-month incidence of all-cause death and cardiogenic death were higher in patients with thrombocytopenia than those without thrombocytopenia; (3) although the incidence of moderate or severe thrombocytopenia was low in our study, it was associated with a six-fold increased risk for all-cause death, 13-fold increased risk for cardiogenic death, seven-fold increased risk for stent thrombosis, and 11-fold increased risk for MI; and (4) by multivariate analysis, we found that baseline creatinine clearance, platelet count, and diabetes mellitus history were independent predictors of post-PCI thrombocytopenia.
The literature shows a variation in the reported incidence of acquired thrombocytopenia, depending on the study's population and definition of thrombocytopenia. In four previous large clinical trials that defined thrombocytopenia as a nadir platelet count of <100 3 10 9 /L, the occurrence of thrombocytopenia ranged from 2.4% to 4% [11] [12] [13] [14] .
Recently, two large clinical trials used a nadir platelet count of <150 3 10 9 /L as diagnostic criteria and observed incidences of thrombocytopenia at 6.8% and 13% [4, 6] . In addition to absolute platelet count, the thrombocytopenia definition of some studies included a relative reduction of 50% from baseline, which identified patients with a significant degree of compromised platelet count despite a nadir within the normal range [15, 16] .
In our study, the incidence of acquired thrombocytopenia was 7.91% and the incidence of mild thrombocytopenia was 7.67%, which was similar to previous trials; however, the incidence of moderate or severe thrombocytopenia in our study was significantly lower than that in previous trials [4, 6, [11] [12] [13] [14] . This discrepancy may be explained by the difference in study population. Compared with previous studies that included high-risk ACS patients, our study included patients with stable angina or low-risk ACS who were less likely to take glycoprotein IIb/IIIa inhibitors or heparin or to have undergone IABP insertion. In addition, patients with normal baseline thrombocytopenia were excluded from our study. These two reasons may contribute to the low incidence of moderate or severe thrombocytopenia in our study.
Many previous studies used a platelet count <100 3 10 9 /L as diagnostic criteria, whereas our study defined thrombocytopenia as a platelet count <150 3 10 9 /L because this value is the lower limit of the normal platelet count range [17, 18] . The definition used in our study may identify more patients at risk of thrombocytopenia, which would be useful for implementing early treatment. As previously mentioned, some studies used the relative reduction of platelet count to define thrombocytopenia [15, 16] . This definition, which is independent of baseline nadir platelet count, may be a more suitable method for identifying at risk patients; however, further validation is required. Many previous studies have reported that thrombocytopenia is associated with increased mortality risk. Tracy Y. Wang et al. described a two-fold increase of in-hospital mortality in patients with mild thrombocytopenia and a 10-fold increased risk for mortality in patients with severe thrombocytopenia from the CRUSADE registry [6] . Data from the observational ACUITY registry suggested thrombocytopenia is associated with a four-fold increased risk for mortality at 14-day follow-up and a roughly three-fold increased risk at one-year followup [4] . In our study, compared with non-thrombocytopenic patients, we observed significantly higher mortality among patients with thrombocytopenia at 30-month follow-up. After multivariable Cox regression analysis, moderate or severe thrombocytopenia was associated with a six-fold increased risk for all-cause death and 13-fold increased risk for cardiogenic death, and mild thrombocytopenia was associated with a two-fold increased risk in all-cause death. In contrast, there was no significant association between mild thrombocytopenia and cardiogenic death after adjustment for differences in patient characteristics, suggesting the impact of thrombocytopenia on patient long-term outcomes depends on the severity of thrombocytopenia.
Several potential mechanisms may explain why thrombocytopenia was associated with higher mortality. First, platelet activation during their consumption may lead to downstream thrombotic events [19] . In addition, patients who develop thrombocytopenia are at higher bleeding risk and are less likely to receive guideline-recommended therapies and PCI. Furthermore, the effect of thrombocytopenia on mortality group [6] . The ACUITY trial suggested patients with mild or moderate acquired thrombocytopenia had a three-fold higher incidence of non-CABG major bleeding, and those who developed severe acquired thrombocytopenia had a seven-fold higher rate of non-CABG major bleeding at 30-day follow-up [4] . However, in our study, the incidence of major bleeding was nearly the same (1.2% vs. 1.4%) between patients with vs. without thrombocytopenia, and no patient developed bleeding in the moderate or severe thrombocytopenia group. This low major bleeding rate in our study may be explained by the difference in study populations. In our study, we enrolled patients undergoing elective PCI whereas previous studies enrolled patients with acute coronary syndrome. Therefore, our study population may have fewer risk factors for major bleeding, including creatinine clearance, heart rate, diabetes history, and prior vascular disease. This was further demonstrated by the very low incidence of moderate or severe thrombocytopenia post-PCI in our study. clearance and low platelet count at admission has been previously described [22] . Potential mechanisms for thrombocytopenia in patients with renal dysfunction includes intrinsic platelet dysfunction, reduced platelet aggregation, and abnormalities in platelet-endothelial interactions [23] . Hypoglycemic medication was proposed as one mechanism regarding the increased risk of thrombocytopenia among diabetic patients. Previous studies have described that severe thrombocytopenia is related to treatment with glibenclamide, an oral hypoglycemic agent [24] . Our results suggested that clinicians should be aware of post-PCI thrombocytopenia risk among patients with initial low platelet counts, renal insufficiency, and diabetes during hospital stay.
| LI M I TA TI ON S
There are several limitations of the current study. First, this was a post hoc analysis, so the results can be considered for generating research hypotheses, but they require confirmation with additional studies.
Second, the number of patients who developed moderate or severe thrombocytopenia was relatively small. Third, the cause of the thrombocytopenia was not investigated in every case. 
| CON CL U S I ONS
